Managing Movement Disorders in the older patient

Similar documents
Optimizing Clinical Communication in Parkinson s Disease:

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Non-Motor Symptoms of Parkinson s Disease

Moving fast or moving slow: an overview of Movement Disorders

Issues for Patient Discussion

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Alison Charleston 1 st September 2016

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Part I Parkinson Disease Diagnosis and Treatment

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Parkinson s Disease. Gillian Sare

The PD You Don t See: Cognitive and Non-motor Symptoms

Best Medical Treatments for Parkinson s disease

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

The PD You Don t See: Cognitive and Non-motor Symptoms

Parkinson s Disease Current Treatment Options

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Understanding Parkinson s Disease Important information for you and your loved ones

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

PARKINSON S DISEASE OVERVIEW, WITH AN EMPHASIS ON PHYSICAL WELLBEING. Gillian Quinn MISCP, Senior Physiotherapist in Neurology, SVUH

Communicating About OFF Episodes With Your Doctor

Treatment of Parkinson s Disease: Present and Future

Appendix N: Research recommendations

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

Evaluation of Parkinson s Patients and Primary Care Providers

Headway Victoria Epilepsy and Parkinson s Centre

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Multiple System Atrophy

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

What is dementia? What is dementia?

Dr Barry Snow. Neurologist Auckland District Health Board

Prior Authorization with Quantity Limit Program Summary

Parkinson's Disease KP Update

Elements for a Public Summary

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Parkinson s disease. Quick reference guide. Issue date: June Diagnosis and management in primary and secondary care

FALLs in Parkinson s Disease (PD)

PD AND FALLS J U MALLYA FALLS AWARENESS MEETING

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

III./3.1. Movement disorders with akinetic rigid symptoms

Elements for a public summary

Faculty. Joseph Friedman, MD

Parkinson s for Care Staff

PARKINSON S MEDICATION

Pain in dementia. Prof Rowan Harwood Geriatrician, NUH. Disclaimer

2015 UK Parkinson s Audit Patient and carer report

Behavioral Aspects of Parkinson s Disease

Parkinson s Disease Foundation. PD ExpertBriefing: Managing the Motor Symptoms in PD

DYSKINESIA SYMPTOM TRACKER

SECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden *

DOCTOR DISCUSSION GUIDE

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

Joint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD

Evaluation and Management of Parkinson s Disease in the Older Patient

10th Medicine Review Course st July Prakash Kumar

If you have dementia, you may have some or all of the following symptoms.

What is dementia? What is dementia?

Helpful Tips for the Unsteady Patient. Mairead Collins Senior Physiotherapist Bon Secours Hospital 20/09/14

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

Differential Diagnosis of Hypokinetic Movement Disorders

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease

MULTIPLE SCLEROSIS INTRODUCTION OBJECTIVES. When the student has finished this module, he/she will be able to:

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

IMPORTANT: PLEASE READ

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

The Person: Dementia Basics

Psychiatric aspects of Parkinson s disease an update

SNOEZELEN FOR THE PEOPLE WITH PARKINSON'S DISEASE

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM

Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Multiple choice questions: ANSWERS

TREANA 5mg and 10mg Film-coated Tablets

Pilates as a modality to increase movement and improve quality of life for those suffering from Parkinson s Disease

EXERCISE FOR PARKINSON S RECOMMENDATIONS FOR MANAGING SYMPTOMS

Origins. Update on Parkinson s Disease

Delirium Information for relatives, carers and patients

Ratified by: Care and Clinical Policies Date: 17 th February 2016

PATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE

Understanding Dementia

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

DEBORAH MCKERN. Aged Care Consultant

Clinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries

Parkinson s National Audit 2015

Dementia: It s Not Always Alzheimer s

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Transcription:

Managing Movement Disorders in the older patient Dr Jan Gregson 24 November 2017 With thanks to Dr Kirsten Holst, Physician and Geriatrician, MidCentral DHB

I guess I am not an expert in the area of prescribing for PD, but there is a huge population of people with it in Levin, that I inherited from a retired colleague... they cause me a lot of stress.

First described by James Parkinson in 1817 monograph: "An Essay on Shaking Palsy

What Parkinson said Involuntary tremulous motion Lessened muscular power Propensity to bend the trunk forwards Propensity to pass from a walking to a running pace Senses and intellects uninjured

What modern literature says Progressive neurodegenerative disease Affects up to 200 per 100,000 people aged over 40 Uncommon in people younger than 40 Incidence increases rapidly in those over 60 Mean age at diagnosis is 70.5 years Traditionally been considered a motor system disorder Now recognised to be complex with diverse clinical features that include neuropsychiatric and other non-motor manifestations in addition to its motor symptomatology. Accurate diagnosis rests on recognition of characteristic symptoms and signs

Results from progressive failure of dopamine-generating cells in the substantia nigra and associated neural pathways. clinical picture dictated by the variable degree to which the pathways are involved

Clinical features 1: motor Tremor Rigidity Bradykinesia Postural instability Festination Forward-flexed posture Speech and swallowing disturbances Mask-like face expression with decreased spontaneous blinking Small handwriting

Clinical features 2: Neuropsychiatric (of which more from Dr Johnson later!) Cognitive disturbances including dementia (2 6 times risk): executive dysfunction, loss of cognitive flexibility, and abstract thinking, inappropriate selection of sensory information, reduced attention, slowed cognitive speed, reduced memory, visuo-spatial difficulties. Mood disturbance: depression, anxiety, impulse control issues (binge eating, hypersexuality, pathological gambling). Psychosis: hallucinations, illusions, delusions. Behavioural disturbance: agitation, aggression

Clinical features 3: other Sleep problems: daytime drowsiness, insomnia, REM sleep disorder Autonomic dysfunction: orthostatic hypotension, oily skin, excessive sweating, incontinence, constipation, altered sexual function. Ocular issues: decreased blink rate, dry eyes, tracking and saccadic problems, blurred vision, double vision. Perceptual problems: anosmia, paraesthesia, pain.

So why does managing PD stress us Treating people with PD is often easy in the first 7 years... everything tends to work, but after that you get into trouble. The language patients use is difficult. I find it hard to work out if problems are over- or under-dose. Plus, people with PD are very attached to their medication, and they want it increased when things are not good this is not always helpful.

Mr J 79 year old man PD for 8 years. Also has AF. Medications: Madopar 250mg SR bd Benztropine 4mg nocte Dabigatran 150mg bd. Presents to ED with dizziness on first standing and 2 episodes of LOC resulting in falling to the floor. Lying BP 116/55 Standing BP 64/38. No change in HR.

Admitted to the Medical Ward. Advised to increase oral fluid intake and add salt to food. Provided with compression stockings. Benztropine stopped. Fludrocortisone 0.1mg started. Symtpoms improved over 72 hours. Lying BP 131/69. Standing BP 97/53. Discharged home.

Seen in OPD 4 weeks later. Still dizzy on standing but no LOC or falls. Has restarted Benztropine as noted marked worsening of PD symptoms. Says he simply could not function without it, but cannot provided specifics of impairments. Independent with transfers, mobility, personal cares and domestic tasks. Seated BP 90/70. Standing BP 60/40.

Adamant he will not come off or even reduce Benztropine. Started on Midodrine 2.5mg tds. Reviewed 6/52 later. Feels much better. No dizziness. No syncope. No falls. Seated BP 100/70. Standing BP 90/60.

Extremely unhappy! Angry that he is getting a tablet to treat a tablet. Wants to stop Midodrine. Does not want to stop Benztropine. Attempted to reassure and re-educate. Offered another opinion declined. Offered another appointment. DNA.

They also often have managed their medications independently, so even if they are with a partner, the partner doesn't always really know what is going on. You can't make changes and not follow-up, so it is self perpetuating that you see them, twiddle and then need to see them again.

Dopamine is important in reward systems, so withdrawing medication isn't always pleasant it is important to do it slowly (weeks and months). The trouble is often associated with cognitive decline (if you have it long enough, you will get cognitive decline) and balancing the movement disorder with cognitive disorder is tricky... it stops just being a movement disorder that you are managing.

Mr H Inherited from Neurology when he turned 65. On madopar, pergolide and amantidine. Some concerns with impaired cognition and insight, specifically that he was driving and hunting episode when armed defenders had been mobilised due to significant hallucinations. Temporarily improved with donepezil some difficulty getting him to decrease medications.

Mobility issues complicated by osteoarthritis in knee had knee surgery, and was in AT&R (easier to change medication as inpatient). Concern raised that his wife did not want sex as much as he did (I don't often ask about sex, he told me this with his wife there). She died soon after and there were issues with sexually inappropriate advances to granddaughter and carers.

Mrs S Late 60s. Very physically debilitated secondary to intracranial haemorrhage following insertion of deep brain stimulator 10 years prior Wheel chair dependent, mute, dystonic posturing of left side,cared for at home by husband. On madopar, pergolide and amantidine

Having blank episodes in the shower? postural hypotension? Seizure. Valproate helped so likely latter. Pressure sore on chest wall associated with DBS battery, adjacent breast tissue and spastic arm. Botox to help release spasm helped. Removal of battery was complicated by wire protruding wound. Very slow decrease in pergolide and amantidine

Mrs T 80s Lives with husband 10+ years of PD Presented with fall, where she and husband got tangled and he landed on her. Fractured ribs with haemopneumothorax, managed with intercostal drain. Delirium while inpatient, improved with donepezil but then issues with urinary retention so this was stopped. Trial of care at home unsuccessful, has gone into residential care.

Non-medical treatment options Relaxation techniques can reduce rigidity. Regular physical exercise can be beneficial to maintain and improve mobility, flexibility, strength, gait speed, and quality of life. Physiotherapy produces additional improvements in motor symptoms. gait speed, base of support, stride length, trunk and arm swing movement. utilises strengthening exercises, respiratory exercises, assistive equipment (pole walking and treadmill walking), verbal cueing (manual, visual and auditory), altering environments. Needs to be co-ordinated with medication, ideally 45 minutes to one hour after Speech and Language Therapy Lee Silverman voice treatment (LSVT) Occupational Therapy techniques for padl, provision of equipment, advice on home adaptation

Medical treatment (of which more later from Dr Bourke!) Levodopa remains mainstay in older people Most widely used treatment for over 30 years (commonly as Sinemet and Madopar which have additional components) Converted into dopamine by dopa-decarboxylase Most does not reach the brain Temporarily reduces motor symptoms Side effects: Due to breakdown before reaching the brain: nausea, dyskinesia, joint stiffness. Due to compulsive overuse: dopamine dysregulation syndrome

Particular things dealing with older PD patients Check cognition when things start to decline. Stopping amandine or pergolide may help with this. Consider donepezil. Simplify medication by using long acting preparations or tolcopone / entacapone. Change one thing at a time. Talk with carers about hallucinations and other behavioural symptoms that occur in PD and with PD treatment e.g. infidelity, spending, gambling. I quite like the explanation that as you get cell death with PD you may not need so much medication to have effect, giving you the opportunity to decrease medication. I also remind people that it is a progressive, neurological degenerative condition and that it will get worse. What we are doing is managing problems and this may not be PD or medication.